Publicaciones en colaboración con investigadores/as de Hospital del Mar (9)

2022

  1. Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

    Gynecologic Oncology, Vol. 166, Núm. 1, pp. 36-43

  2. Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study

    BMC Cancer, Vol. 22, Núm. 1

2021

  1. Elective Cancer Surgery in COVID-19-Free Surgical Pathways during the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study

    Journal of Clinical Oncology, Vol. 39, Núm. 1, pp. 66-78

2016

  1. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

2015

  1. Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer

    Current Medical Research and Opinion, Vol. 31, Núm. 6, pp. 1129-1137

2012

  1. Prospective transGEICAM study of the impact of the 21-gene recurrence score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer

    Annals of Oncology, Vol. 23, Núm. 3, pp. 625-631

2010

  1. Treatment of cancer with oral drugs: A position statement by the Spanish Society of Medical Oncology (SEOM)

    Annals of Oncology

2009

  1. Guidelines for HER2 testing in breast cancer: A national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 11, Núm. 6, pp. 363-375

2008

  1. A phase II trial of fixed-dosed rate gemcitabine in platinum-resistant ovarian cancer: A GEICO (Grupo Español de Investigación en Cáncer de Ovario) trial

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 31, Núm. 5, pp. 481-487